FIGO Staging – Gynecologic Cancers (Simplified)
Educational tool to approximate FIGO stage groups (I–IV) for ovarian, endometrial, and cervical cancers based on overall extent of disease. For trained health professionals only.
- Stage I – Tumor confined to the organ of origin.
- Stage II – Direct extension into adjacent pelvic organs / tissues.
- Stage III – Regional spread (e.g. pelvic/para-aortic nodes, pelvic/abdominal peritoneum).
- Stage IV – Invasion of bladder/rectal mucosa and/or distant metastases.
Stage Group & Interpretation
Select the cancer type and the best-fitting extent description, then click “Calculate FIGO Stage Group” to see the simplified stage and narrative interpretation.
This tool is intended purely as an educational adjunct for clinicians already familiar with FIGO staging. It approximates stage groups only and does not substitute for full staging guidelines, multidisciplinary discussion, or national/international protocols. It must not be used by patients or families for self-staging or prognosis.
The FIGO (International Federation of Gynecology and Obstetrics) Staging System is the global standard for classifying the extent and spread of gynecologic malignancies. Unlike many other cancers that may use clinical staging (based on physical exams and imaging), most FIGO stages are surgical-pathological, meaning the final stage is determined after surgery and a detailed microscopic examination of the tissue (Bhatla et al., 2021).
Proper staging is critical because it dictates the entire treatment roadmap—from the extent of surgery to the need for chemotherapy or radiation.
The Core Framework of FIGO Staging
While each gynecologic cancer (Cervical, Endometrial, Ovarian, Vaginal, and Vulvar) has its own specific nuances, they all follow a consistent four-stage numerical hierarchy.
Shutterstock
Explore
General Stage Definitions
| Stage | Extent of Disease | Typical Clinical Picture |
| Stage I | Confined | The tumor is strictly limited to the organ of origin (e.g., only in the ovary or only in the cervix). |
| Stage II | Local Spread | The tumor has spread to nearby pelvic organs or tissues within the pelvic cavity. |
| Stage III | Regional Spread | The tumor has spread to the lymph nodes (pelvic or para-aortic) or distant parts of the abdominal cavity. |
| Stage IV | Distant Metastasis | The cancer has spread to distant organs like the lungs, liver, or bone, or into the mucosa of the bladder/rectum. |
Site-Specific Staging Highlights
1. Cervical Cancer (Revised 2018)
The 2018 revision was a major shift, allowing for the use of imaging (MRI/CT) and pathological findings to assign the stage. A key change was that Stage IIIC now specifically denotes involvement of the lymph nodes, regardless of the size of the primary tumor (Bhatla et al., 2018).
2. Endometrial (Uterine) Cancer (Revised 2023)
The newest update in 2023 represents a “paradigm shift” by incorporating molecular markers (like POLE mutations or p53 status) into the staging. This allows for a more personalized prognosis, as a small tumor with an aggressive molecular profile may now be staged more severely than in previous years (Berecek et al., 2023).
3. Ovarian, Fallopian Tube, and Peritoneal Cancer
These are staged together because they behave similarly. Stage III is common at diagnosis and is defined by “peritoneal implants” outside the pelvis—essentially small seeds of cancer spread across the surface of the intestines or liver.
Clinical Significance: Why Staging Matters
- Prognosis: Survival rates are heavily tied to the FIGO stage. For example, Stage I endometrial cancer has a 5-year survival rate of over 90%, whereas Stage IV drops significantly.
- Treatment Selection: * Early Stages (I-II): Often managed with primary surgery (Hysterectomy, Oophorectomy).
- Advanced Stages (III-IV): Often require “multimodal” therapy, combining debulking surgery with systemic chemotherapy or targeted biological agents.
- Standardization: It allows researchers in different countries to compare clinical trial results using a “common language.”
References
- Bhatla, N., et al. (2021). FIGO cancer report 2021. International Journal of Gynecology & Obstetrics, 155(S1), 1-214. https://doi.org/10.1002/ijgo.13865
- Bhatla, N., et al. (2018). Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology & Obstetrics, 143(3), 325-335.
- Berecek, K., et al. (2023). FIGO staging of endometrial cancer: 2023 release. International Journal of Gynecology & Obstetrics, 161(3), 715-726. https://doi.org/10.1002/ijgo.14745
- Prat, J., & FIGO Committee on Gynecologic Oncology. (2014). Staging classifications for cancer of the female reproductive organs. International Journal of Gynecology & Obstetrics.
